Drug Development
Enrollment completed in second phase III AzaSite study
Published in Drug Week, February 10th, 2006
This second phase III clinical study was a randomized, double blind, vehicle-controlled study evaluating the safety and efficacy of AzaSite in patients with bacterial conjunctivitis. The randomized patients were treated for 5 days, twice daily for the first 2 days followed by once per day for days 3-5, with either AzaSite or a vehicle formulation. The goal of the study is to demonstrate superiority of AzaSite as...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-02-10)
More Articles from Drug Week
- Chlamydia Pneumonia
A novel phenoxazine derivative may be useful for controlling Chlamydia pneumoniae - Clarithromycin
Non-irradiated mice fared better with therapy for Bacillus anthracis Sterne infection - Drug Development
ACR16 receives orphan drug designation in the U.S. for Huntington disease - Drug Development
Approval granted to commence phase III study of Androxal for testosterone deficiency - Gene Expression
Neuropeptide gene expression in response to acute drug challenge may include modulation of behavioral effects - Acute Bacterial Sinusitis
Biopharma company submits NDA for Orapem to treat respiratory tract and skin infections - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
